Das estnische Genomprojekt im Kontext der europäischen   Genomforschung

A. Metspalu; F. Köhler; G. Laschinski; D. Ganten; I. Roots

doi:10.1055/s-2004-824840

DMW - Deutsche Medizinische Wochenschrift, Table of Contents

Dtsch Med Wochenschr 2004; 129: S25-S28
DOI: 10.1055/s-2004-824840

Übersichten

Das estnische Genomprojekt im Kontext der europäischen Genomforschung

The Estonian Genome Project in the context of European genome researchA. Metspalu¹ , F. Köhler² , G. Laschinski³ , D. Ganten⁴ , I. Roots³

¹Estonian Genome Project Foundation, University of Tartu and Estonian Biocentre, Tartu, Estonia
²Charité -Universitätsmedizin Berlin, Medizinische Klinik mit Schwerpunkt Kardiologie, Pulmologie und Angiologie, Campus Charité Mitte, Berlin
³Institut für Klinische Pharmakologie, Charité - Universitätsmedizin Berlin, Campus Charité Mitte, Berlin
⁴Charité -Universitätsmedizin Berlin, Vorstandsvorsitzender, Campus Charité Mitte, Berlin

Abstract

Summary

It is the aim of the Estonian Genome Project to establish a database which compiles phenotype and genotype data of a large part of the Estonian population. The Gene Bank will only be used for scientific and public health research. Researchers hope that it will help identify disease genes and prepare the ground for the personalized medicine of the future. Additionally, the project will improve Estonian’s international competitiveness in high technology and have a strong educational effect on the population. The legal framework, the Human Genes Research Act, was passed by the Estonian parliament in December 2000. It had been drafted by a group of experts who took into account all available international guidance documents on genetic research. With the pilot project involving three selected regions successfully finished, the main project has now started.

Full Text

References

Literatur

1 Aynacioglu A S, Nacak M, Filiz A, Ekinci E, Roots I. Protective role of glutathione S-transferase P1 (GSTP1) Val105Val genotype in patients with bronchial asthma. Br J Clin Pharmacol. 2004; 57 213-217
2 Brockmöller J, Cascorbi I, Henning S, Meisel C, Roots I. Molecular genetics of cancer susceptibility. Pharmacology. 2000; 61 212-227
3 Collins F S, Green E D, Guttmacher A E, Guyer M S. A vision for the future of genomics research. Nature. 2003; 422 835-847
4 Conney A H. Tailoring cancer chemoprevention regimens to the individual. J Cell Biochem. 2004; 97 277-286
5 Cusi D, Barlassania C, Azzani T, Casari G, Citterio L, Devoto M, Glorioso N, Lanzani C, Manunta P, Righetti M, Rivera R, Stella P, Troffa C, Zagato L, Bianchi G. Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet. 1997; 349 1353-1357
6 Dawson E, Abecasis G R, Bumpstead S, Chen Y, Hunt S, Beare D M, Pabial J, Dibling T, Tinsley E, Kirby S, Carter D, Papaspyridonos M, Livingstone S, Ganske A, Rice K, Deloukas P, Mott R, Metspalu A, Bentley D R, Cardon L R, Dunham I. A first-generation linkage disequilibrium map of human chromosome 22. Nature. 2002; 418 544-548
7 Estonian Genome Project Foundation. http://www.geenivaramu.ee
8 Freimer N, Sabatti C. The human phenome project. Nature Genetics. 2003; 34 15-21
9 Gasparini P, Rabionet R, Barbujani G, Melchionda S, Petersen M, Brondum-Nielsen K, Metspalu A, Oitmaa E, Pisano M, Fortina P, Zelante L, Estivill X. High carrier frequency of the 35delG deafness mutation in European populations. Genetic Analysis Consortium of GJB2 35delG. Eur J Hum Genet. 2000; 8 19-23
10 Gong M, Zhang H, Schulz H, Lee Y A, Sun K, Bähring S, Luft F C, Nürnberg P, Reis A, Rohde K, Ganten D, Hui R, Hübner N. Genome-wide linkage reveals a locus for human essential (primary) hypertension on chromosome 12p. Human Molecular Genetics. 2003; 12 1273-1277
11 Kaiser J. BIOBANKS: Population databases boom, from Iceland to the US. Science. 2002; 298 1158-1161
12 Katzov H, Chalmers K, Palmgren J, Andreasen N, Johansson B, Cairns N J, Gatz M, Wilcock G K, Love S, Pedersen N L, Brookes A J, Blennow K, Kehoe P G, Prince J A. Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to β-amyloid metabolism. Human Mutation. 2004; 23 358-367
13 Kirchheiner J, Meisel C, Goldammer M, Gerloff T, Kaiser R, Roots I. Pharmakogenetik als Basis neuer Therapiekonzepte. Bundesgesundheitsblatt. 2003; 46 835-844
14 Meisel C, Gerloff T, Kirchheiner J, Mrozikiewicz P M, Niewinski P, Brockmöller J, Roots I. Implications of pharmacogenetics for individualizing drug treatment and for study design. J Mol Med. 2003; 81 154-167
15 Merz J F, McGee G E, Sankar P. „Iceland Inc.”?: On the ethics of commercial population genomics. Social Science and Medicine. 2004; 58 1201-1209
16 Tobin M D, Braund P S, Burton P R, Thompson J R, Steeds R, Channer K, Cheng S, Lindpaintner K, Samani N J. Genotypes and haplotypes predisposing to myocardial infarction: a multilocus case-control study. European Heart Journal. 2004; 25 459-467
17 Tonisson N, Zernant J, Kurg A, Pavel H, Slavin G, Roomere H, Meiel A, Hainaut P, Metspalu A. Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor gene. Proc Natl Acad Sci USA. 2002; 99 5503-5508

Prof. Dr. Andres Metspalu

Institute of Molecular and Cell Biology, University of Tartu

23 Riia Str.

EE-51010 Tartu, Estonia